AMX the undisputed leader of the Mexican telecom market, recently won approval from Mexican telecom regulator Federal Telecommunications Institute (popularly known as IFT), regarding the prices the company can charge as its interconnection fees.
Notably, interconnection fees are the prices that a carrier is allowed to charge other telecom operators or mobile virtual network operators with, to connect to its network. Large telecom operators generally have vast networks across the nation. Smaller operators or MVNOs, at times, share this network to offer their services without deploying their own network. For this, these small-sized service providers need to pay certain stipulated fees to their larger peers.
In 2014, the government of Mexico introduced reforms within its telecommunications sector. The IFT identified America Movil as the dominant player in this market. The company’s wireless division, Telcel, holds about 70% of the market share. Notably, per the reformed norms, the IFT restricts the maximum hold of a company in the market to 50%.
As part of these reforms, the IFT also banned America Movil from charging national roaming fees. Further, the company will have to share its infrastructure with other operators particularly in the local loop (last mileage) segment. Interconnection fees levied by the company had been under close scrutiny as well.
Full content: Zacks
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas